{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"7.4","value":"4.2"},{"groupId":"OG002","lowerLimit":"1.9","upperLimit":"4.9","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Non-small cell lung cancer (NSCLC)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"5.6","value":"5.4"},{"groupId":"OG002","lowerLimit":"1.8","upperLimit":"3.7","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"11.1","value":"5.8"},{"groupId":"OG002","lowerLimit":"1.6","upperLimit":"3.9","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"Renal cell cancer (RCC)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"7.4","value":"5.6"},{"groupId":"OG002","lowerLimit":"1.8","upperLimit":"5.7","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Mesothelioma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"3.8","value":"1.9"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"3.6","value":"1.9"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"3.4","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Triple negative breast cancer (TNBC)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.\n\nTumor response was based on local investigator assessment and the assessment criteria was irRC.\n\nPFS is reported by tumor type.","dispersionType":"90% Confidence Interval","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEDIAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 or PDR001.","reportingStatus":"POSTED","timeFrame":"From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years","title":"Phase 2: Progression-free Survival (PFS) Per irRC","type":"SECONDARY","unitOfMeasure":"months"}